HD IL-2 dose limiting toxicities reported for cycle 1 of treatment
| Ipi only (n = 52) | No prior ICB (n = 276) | Total (n = 328) | ||||
|---|---|---|---|---|---|---|
| Cardiac | 13 | 18.57 | 84 | 24.56 | 97 | 23.33 |
| Renal | 12 | 17.14 | 51 | 14.91 | 63 | 15.29 |
| Neurologic | 5 | 7.14 | 52 | 15.2 | 57 | 13.83 |
| Gastrointestinal | 10 | 14.29 | 36 | 10.53 | 46 | 11.17 |
| Hematologic | 7 | 10 | 34 | 9.94 | 41 | 9.76 |
| Metabolic | 5 | 7.14 | 30 | 8.77 | 41 | 9.76 |
| Pulmonary | 10 | 14.29 | 19 | 5.6 | 29 | 7.38 |
| Capillary Leak Syndrome | 2 | 2.86 | 17 | 4.97 | 19 | 4.52 |
| Hepatic | 2 | 2.86 | 13 | 3.8 | 15 | 3.57 |
| Skin | 4 | 5.71 | 6 | 1.75 | 10 | 2.38 |
| Total | 70 | 100 | 342 | 100 | 412 | 100.0 |
The first column represents the number of times a toxicity was reported among the entire cohort of patients. The second is the percentage of each individual toxicity as compared to the total number of events. The total events add up to more than the number of patients as some patients reported more than one dose limiting toxicity, up to a maximum of three